ALSO NOTED: Dusa, River's Edge settle patent claims; Abaxis appoints new operating VP;

> Dermatological drug maker Dusa Pharmaceuticals has settled a patent-infringement claim with River's Edge Pharmaceuticals, which has been selling a copycat form of Dusa's Nicomide acne med. Report

> Abaxis, which makes portable blood-analysis devices, has hired a new vice president of operations, Donald P. Wood. Report

> Indian regulators who've been cracking down on price-controlled drugs found that more than half the products it sampled were overpriced or had no government-approved pricing. Report

> After five years in partnership with Roche, Kosan Biosciences says it will seek a new partner for its experimental cancer therapy epothilone. Report

> Amid the upbeat tone to yesterday's release of third quarter income at Bristol-Myers Squibb, executives hit a sour note with their announcement that they would probably not seek FDA approval of their bladder drug vinflunine. Report

> With sales of Aranesp and Epogen on the decline, biotech giant Amgen is feeling the impact right where it hurts the most: The bottom line. Report

And Finally... The saga of drug-resistant staph continues--in Fido and Muffin. Vets say cases of MRSA infections in animals are on the rise, too. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.